The Use of PARP Inhibitors in Breast Cancer
Clinical Spotlight
Clinical Spotlight

The Use of PARP Inhibitors in Breast Cancer

Key Updates From the 2017 Oncology Annual Meeting in Chicago

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

This breast cancer thought-leader discussion, with associated slide deck and eNewsflash, provides participants with valuable updates and expert perspectives on exciting new data on the use of PARP inhibitors in breast cancer released at the 2017 Oncology Annual Meeting in Chicago.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Newsflash

Newsflash

Release Date

Release Date

Jun 8, 2017

Expiration Date

Jun 9, 2018

Abstract LBA4: OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

Featured Experts

  • Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
    University of Sheffield
    Weston Park Hospital
    Sheffield, United Kingdom
  • Pierfranco Conte, MDIstituto Oncologico Veneto
    University of Padua
    Padua, Italy
  • Andrew Tutt, MD, PhDInstitute of Cancer Research
    London, United Kingdom

After successful completion of this educational activity, participants should be able to:

  • Identify current and emerging treatment options for patients with HER2-negative metastatic breast cancer
  • Describe the impact of BRCA 1/2 testing on clinical outcomes for patients with breast cancer
  • Assess recent and ongoing clinical trial data of PARP inhibitors in patients with breast cancer
  • Select optimal treatment options for patients with triple-negative and BRCA-mutated breast cancer, based on current treatment guidelines and emerging clinical trial data

This educational activity is supported by a grant from AstraZeneca.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.